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Aims: To synthesize the empirical evidence on the effectiveness of shared decision making
(SDM) compared to usual care for prostate cancer (PC) treatment.
Methods and results: A systematic review of academic (MEDLINE, EMBASE,
Cochrane Library, CINHAL, PsychINFO, and Scopus) and grey (clinicaltrials.gov, WHO
trial search, meta-Register ISRCTN, Google Scholar, opengrey, and ohri.ca) literature, also
identiﬁed from contacting authors and hand-searching bibliographies. We included rando-
mized controlled trials (RCTs): 1) comparing SDM to usual care for decisions about PC
treatment, 2) conducted in primary or specialized care, 3) fulﬁlling the key SDM features,
and 4) reporting quantitative outcome data. Four RCTs from Canada (n=3) and the USA
were included and comprised 1,065 randomized men, most (89.8%) of whom were in PC
stage T1-T2. The studies reported 24 outcome measures. In 62.5% study estimates, SDM
was similar to usual care at improving patient satisfaction and mood, and at reducing
decisional conﬂict and decisional regret. In 37.5% study estimates, SDM signiﬁcantly
improved knowledge, perception of being informed and patient-perceived quality of life
(QoL) at four weeks. There was a dearth of outcome data, particularly on the adherence to
treatment and on patient-important and clinically relevant health outcomes such as symp-
toms and mortality.
Conclusion: SDM may positively inﬂuence men’s knowledge and may have a positive but
short-term effect on patient-perceived QoL. The (long-term) effects of SDM on patient-
related outcomes for decisions about PC treatment are unclear. Future research needs
consensus about the interventions and outcomes needed to evaluate SDM and should address
the absence of evidence on health outcomes.
Keywords: systematic review, shared decision making, prostate cancer, treatment, controlled
clinical trials, urology
Introduction
Prostate cancer (PC) is the second leading cancer in men and the ﬁfth leading cause
of death due to cancer in men worldwide.1,2 Patients with PC often face more than
one alternative to treatment eg, active treatment, active surveillance, or watchful
waiting. These choices involve trade-offs between beneﬁts and harms due to the
limited evidence regarding the optimal treatment strategy for PC.3–5 The survival
beneﬁt of treatment options including surveillance is associated with considerable
morbidity due to potential adverse outcomes of treatment (eg, urinary and erectile
dysfunction, loss of fertility, and chemotherapy and/or hormone therapy side
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effects), psychological distress, and impaired quality of
life.3–6 These factors make treatment decisions complex
and highly preference-sensitive. Patients thus need to
weigh carefully not only the diagnoses and prognoses but
also their own fears, values, beliefs, ethics, hopes, and
previous experience.
Shared decision making (SDM) is viewed as an
approach to involve patients and their clinicians in
a process of collaboration and deliberation to reach med-
ical decisions, particularly for preference-sensitive
conditions.7–9 SDM helps inform patients about the
options for, and the effectiveness of, treatment, taking
into account the patient’s needs, knowledge and their
value of risks, beneﬁts, and harms. Health authorities and
policy makers strongly encourage SDM for decisions
about PC treatment.10–13 There is variation in the level of
SDM implementation however, mainly due to the lack of
consensus in SDM deﬁnition and goals.14 We performed
a systematic review to evaluate the evidence for the effec-
tiveness of SDM compared to current clinical practice for
the treatment of PC.
Methods
We followed a protocol based on the principles for sys-
tematic reviews15,16 and report the methods according to
the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines (see Table S1).17
We identiﬁed and selected studies following the methods
published in detail elsewhere.14
Eligibility criteria
We included peer-reviewed and grey literature from
RCTs published in English comparing the effects of
SDM to usual care for decisions about PC treatment,
which were conducted in primary and specialized care
(general practice, community clinics, ambulatory care,
hospital and private). We further limited the inclusion
of studies to RCTs that, regardless of the intervention
target (patients, HCP, surrogates, or family members):
1) met the criteria for SDM9,18 supporting the principle
of bi-directional deliberation,8 as previously illustrated,14
and 2) reported data in quantitative format for the out-
comes of knowledge, patient satisfaction, perception of
being informed, risk perception, decisional conﬂict, deci-
sional regret, outcomes of emotional distress caused by
the disease itself and/or treatment (eg, mood disturbance,
anxiety, and depression), treatment behavior (eg,
adherence to treatment), quality of life (QoL), symptoms,
and mortality.
Study identiﬁcation and search
strategy
We searched for studies in: 1) academic databases:
MEDLINE (Ovid), EMBASE (Elsevier), CINHAL
(EBSCOHost), The Cochrane Library (Wiley), PsychINFO
(EBSCOHost) and Scopus up to March 2015 (see Table S2);
and 2) grey literature records (accessed: Feb–Aug, 2016)
from clinicaltrials.gov and ISRCTN, the WHO search portal
(http://apps.who.int/trialsearch), the Ottawa Hospital
Research Institute website (http://www.ohri.ca), Google
Scholar, and the system for Information on Grey Literature
in Europe (http://opengrey.eu/). We additionally searched for
the registration numbers of the trials using Medline and
PubMed. We screened the reference lists of included studies,
relevant reviews, and clinical guidelines, and contacted
(Jun 2015–Jan 2017) the authors of abstracts for which the
full-texts could not be located.
Selection of studies and data
extraction
Two independent reviewers screened all titles and
abstracts, and assessed the full-text of eligible publica-
tions. One reviewer extracted all data and a second
reviewer independently veriﬁed data extractions.
Differences in study selection and data extractions were
resolved by consensus or by involving an arbitrator. We
grouped outcomes into affective-cognitive, behavioral, and
health outcomes following the system by Shay and Lafata
(2015).19
Risk of bias
Two reviewers independently assessed in duplicate the qual-
ity features of the included studies following established
guidelines and resolving differences by discussion.16,20 We
rated the adequacy of core items including generation of
random sequence, concealment of allocation at randomiza-
tion, blinding (patients, health care providers, and outcome
assessors), intention-to-treat (ITT) (if participants were ana-
lyzed based on their original group allocation), follow-up
(same length of time), and if there were attrition rates of
signiﬁcant concern (at least 20%). We also rated whether
studies reported on the deﬁnition of inclusion and exclusion
criteria, “a-priori” sample size calculation, primary and sec-
ondary outcomes, and funding sources.
Martínez-González et al Dovepress
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Data synthesis
There was mostly one study per outcome precluding
the ability to perform meta-analyses. We thus analyzed
the data based on individual trial estimates. Where
data were sufﬁciently reported, we calculated the
unadjusted risk ratios (RR) or the standard mean dif-
ferences (SMD) and the 95% conﬁdence intervals (CI)
assuming a random-effects model in RevMan 5.3.5
software.21
Results
We examined in detail the full-text of 270 articles. Four of
these fulﬁlled the SDM criteria and investigated the com-
parative effectiveness of SDM with usual care (Figure 1).
Study and population
characteristics
The studies were from Canada (n=3) and the USA (n=1), and
comprised 1,065 patients individually randomized to the
Excluded
(n = 2,331)
Academic database 
COCHRANE (n = 436)
MEDLINE (n = 1,367)
EMBASE (n = 393)
CINAHL (n = 20)
PsychINFO (n = 251)
Scopus (n = 338)
Grey literature 
OpenGrey (n = 5)
GoogleScholar (n = 27)
ClinicalTrials.Gov* (n = 91)
WHO-RCTRP* (n = 8)
ISRCTN Register* (n = 21) 
*Trial reg. no. searched for in 
Medline & PubMed
Reference Lists 
SRs & GDLs (n = 225)
Included RCTs (n = 32)
Records screened after duplicates removed 
(n = 2,556)
Total full-texts evaluated (n = 270)
Full-texts excluded (n = 216)
Appraised for SDM criteria (n = 54)
Excluded at data appraisal (n = 50)
Included in review (n = 4)
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lig
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ty
In
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ed
S
cr
ee
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ng
Id
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ic
at
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n
Grey literature
OHRI.ca weblink
sources (n = 57)
Potentially relevant
(n = 33)
Citations (n = 12,842)
Contacting 
authors
Abstracts (n = 11)
Full-texts received
(n = 27)
Eligible for full-text 
evaluation (n = 18)
Eligible for full-text evaluation
(n = 225)
Excluded
(n = 12,809)
Excluded
(n = 15)
Figure 1 Process of identiﬁcation and selection of studies.
Abbreviations: GDL, guidelines; SR, systematic reviews; SDM, shared decision-making.
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intervention groups (Table 1). The patients were recruited
from multidisciplinary or specialized care in hospital or gen-
eral medicine. Three RCTs reported on cancer staging:
89.8% of the men had localized PC (clinical stage T1-
T2),22–24 6.2% were in advanced stage (T3-T4),23 and 4.1%
were of “unknown” clinical stage.22,23 Radical prostatectomy
(36.7%) and watchful waiting (28.5%) were the most fre-
quently selected treatments among 743 men from 2 RCTs, 1
in general (hospital) and 1 in specialized cancer care, respec-
tively. “No treatment” accounted for 25.4% of all options
offered in one study.23 Men had a mean age of 64.6 (SD 7.8),
83.9% were married and at least 53.4% had a minimum of
high school education. The only RCT reporting on ethnicity
included White (71.5%) and Black (28.5%) men. In three
RCTs reporting on employment status, 55.3% of the men
were in full- or part-time employment. In two RCTs, 88.2%
of the participating health care providers were radiation
oncologists and 11.8% were urologists.
Interventions' characteristics
All interventions fulﬁlled the key features of SDM as illu-
strated in detail elsewhere.14 All RCTs used patient-directed
interventions; one included the patients’ partners in the
interventions sessions (Table 1).25 The interventions were
delivered before decision making, within the time of sched-
uled visits23 or before consultations22,24,25 in order to
empower patient participation in decisions. Men were
recommended to review the material before consultation
or were speciﬁcally encouraged to participate in treatment
decisions. Men were advised to bring their signiﬁcant other-
(s) to the consultation in one RCT.25 Three RCTs used
multifaceted interventions on-site22,25 or at home.24 The
interventions were self-administered or delivered by the
research staff or by a nurse. The formats of the interventions
included video, printed paper-based material, interviews,
telephone calls, or audiotape recording. Only one RCT
considered health care literacy for the development or
pilot testing of the interventions.24 One RCT evaluated
two SDM interventions and usual care.24 The content of
the interventions included educational information, eg,
about PC, treatment choices, advantages and disadvantages
of treatment, side effects, and prognosis.
Risk of bias in the methods of
included studies
All trials adequately randomized patients, but only two
reported adequate concealment of allocation, leading to
risk of selection bias in the other trials (Table 2). Only
one RCT blinded patients and physicians, another blinded
patients only, and no study performed or reported on the
blinding of outcome assessors, resulting in high risk of
performance and detection biases. Two RCTs with an
attrition rate of less than 20% did not report on ITT
analyses. Two RCTs had unclear reporting of attrition
rates and ITT techniques. Men in all intervention arms
were followed-up for the same length of time. All trials
reported the participants’ inclusion criteria but only one
trial reported the exclusion criteria too. Two RCTs
reported on the sample size calculation and power. All
RCTs measured the success of interventions by deﬁnition
of primary outcome(s). All RCTs were funded by non-
proﬁt organizations.
Effectiveness of interventions
There were twenty-four outcome measures reported in the
four RCTs (Figure 2). Data were sparsely reported with
one study per outcome, limiting the ability to conduct
meta-analyses. Table 3 shows the effect estimates for
each individual trial.
Affective-cognitive outcomes
Knowledge
One trial implemented two SDM interventions.24 The dif-
ferent components between SDM groups consisted of
nurse telephone calls to patients (treatment direct [TD])
or nurse telephone calls to patients and primary supporting
persons (treatment supplement [TS]). Compared to usual
care, TD signiﬁcantly improved knowledge for PC and
treatment at four weeks (SMD 0.33, 95% CI 0.03 to
0.64, p=0.03) and at three months (SMD 0.35, 95% CI
0.04 to 0.66, p=0.02). TS also showed a small but signiﬁ-
cant improvement in knowledge at four weeks (SMD 0.33,
95% CI 0.02 to 0.64, p=0.04), but not at three months. The
combined effect of both SDM (TD and TS) interventions
showed a signiﬁcant improvement in knowledge at four
weeks (SMD 0.35, 95% CI 0.08 to 0.62, p=0.01) and at
three months (SMD 0.31, 95% CI 0.04 to 0.58, p=0.02).
Patient satisfaction
Individual trial effect estimates showed no signiﬁcant dif-
ference between SDM and usual care in the number of
patients who were satisﬁed with their treatment choice or
who were satisﬁed with the levels of involvement in treat-
ment decision making with the doctor.22 Scores of patient
Martínez-González et al Dovepress
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satisfaction with preparation for decision making were not
signiﬁcant between groups.
Perception of being informed and risk
perception
Individual trial effect estimates showed a small but signiﬁ-
cant effect of SDM when compared to usual care on
patients’ perception of receiving information (SMD 0.20,
95% CI 0.01 to 0.39, p=0.04).23 The same trial showed
a marginal but statistically signiﬁcant effect of SDM on
positive perceptions of receiving information about treat-
ment alternatives (SMD 0.19, 95% CI −0.00 to 0.38,
p=0.05) and treatment side effects (SMD 0.25, 95% CI
0.06 to 0.44, p=0.010). No study reported on risk perception.
Mood state/disturbance, anxiety, and
depression
Outcomes of emotional distress including mood/distur-
bance, anxiety, and depression caused by the personal
situation, the disease itself, or treatment were scarcely
reported. Individual trial effect estimates showed no sig-
niﬁcant differences between SDM (TD or TS) and usual
care with respect to mood state or disturbance at four
weeks or at three months.24 No study reported quantitative
data on anxiety and depression.
Decisional conﬂict
Individual trial effect estimates showed no signiﬁcant dif-
ferences between SDM and usual care in the scores of
decisional conﬂict.22
Decisional regret
Individual trial effect estimates showed no signiﬁcant dif-
ferences between SDM (TD or TS) and usual care in the
scores of decisional regret at three months.24 The com-
bined effect of both SDM (TD and TS) interventions
compared to usual care was not signiﬁcant at three months.
Behavioral outcomes
Adherence to treatment of choice
Radical prostatectomy and watchful waiting were the
most frequent treatments received or chosen by men in
two RCTs.22,23 No trial reported on the adherence to
a treatment initially chosen however.
Health outcomes
Quality of life, symptoms, and mortality
Individual trial effect estimates showed a signiﬁcant
effect of two SDM (TD or TS) interventions, compared
to usual care, on men’s positive feelings about their QoL
at four weeks (TD: SMD 0.50, 95% CI 0.19 to 0.81,
p=0.002; TS: SMD 0.50, 95% CI 0.18 to 0.81,
p=0.002).24 This effect did not sustain at three months
for either of the SDM (TD or TS) interventions however.
Health outcomes of symptoms and mortality were not
reported.
Discussion
In this systematic review, we identiﬁed four RCTs that
both fulﬁlled the criteria for SDM and evaluated the com-
parative effectiveness of SDM with usual care for men
faced with decisions about PC treatment.
Despite the low volume of literature, 37.5% of the
study estimates signiﬁcantly favored SDM when compared
to usual care. We found moderate effects of SDM on
knowledge, perception of being informed, and QoL. The
effects on knowledge and QoL did not sustain at long term
(three months) however. The remaining 62.5% of the study
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estimates showed no signiﬁcant differences between SDM
and usual care on patient satisfaction, decisional conﬂict,
decisional regret, and mood.
This systematic review is based on published data.
Surprisingly, six of the thirteen outcomes of interest were
not reported. Of particular concern is the dearth of outcome
data on the adherence to treatment and health outcomes
including symptoms, mortality and QoL. The methodologi-
cal quality of studies is low to moderate at best, mainly due
to unclear allocation concealment, blinding and attrition.
The interventions varied in characteristics and content, and
were delivered before decision making mostly by trained
nurses or research staff. The description of population char-
acteristics was often incomplete too. The studies were car-
ried out mostly in specialized and hospital care in high-
income countries from North America, mainly Canada. The
ethnicity of the populations was generally not described.
Thus, the evidence is generalizable mostly to middle-aged
men of at least ﬁfty-ﬁve years of age, from Western coun-
tries, married, with low to moderate levels of education,
who have an English-speaking background and face deci-
sion making for PC treatment.
SDM is highly recommended by major task force asso-
ciations, policy makers, and clinical guidelines for medical
decisions regarding PC treatment.10,11,26–30 Our systematic
review, however, reveals a lack and variable reporting of
outcome measures in the included studies, particularly on
health outcomes. This makes it difﬁcult to relate patient
involvement in decision making to the actual effects of
SDM. The inconsistent reporting of outcomes across studies
is most likely due to the lack of consensus in the deﬁnition
and in the approach used to evaluate and implement
SDM.14 SDM is variably adopted in practice as suggested
by the very few studies meeting the key SDM criteria.
Perspectives of the health care team involved in SDM
may play a role in this variability. In a multidisciplinary
survey study, 63–71% of oncology nurses, urologists, and
oncologists agreed that patients should be involved in
decision making.31 However, 52–55% of the urologists
and oncologists felt inadequately trained to apply SDM in
clinical practice. On the other hand, 20% of the oncology
nurses felt inadequately trained to apply SDM. Although an
assessment of economic outcomes was outside the focus of
our review, we noted that no study reported on cost data.
Clinical implications
The variation in the deﬁnitions and goals of SDM14 and
the inconsistent reporting of outcomes across studies are
the main barriers in generating an evidence base for the
effectiveness of SDM in the care of PC patients. Before
implementing SDM in clinical guidelines of PC care and
applying these on a large scale in practice, more efforts in
standardizing the deﬁnition, goals, and outcomes of SDM
are needed. Our results may thus encourage researchers to
engage in this area. The absence of evidence of SDM in
PC care does not prove a lack of its beneﬁcial effects.
Thus, our results about the moderate effects of SDM on
knowledge, perception of being informed and QoL may
still motivate clinicians to activate their PC patients to
participate in decision making.
Future research
Future research warrants further focus on the use of SDM
interventions for decisions about PC treatment. Some
guidance for SDM implementation based on a clear deﬁ-
nition and objectives of SDM as previously reported14
could be the leading step in building focused and solid
evidence on SDM. Agreement on a standard set of out-
comes that are best to assess SDM and that are most
meaningful to patients is critical to guide appropriate
outcome collection and evaluation of SDM. Future
research then needs to address the absence of evidence,
particularly on health outcomes. The link between patient
involvement in decision making and the effect of SDM-
chosen treatment on patient-important and health-related
outcomes needs special consideration. Since treatment
can have a signiﬁcant impact on the patients’ QoL and
length of survival, studies of SDM for PC need to provide
an appropriate description of the characteristics of the
populations including comorbidities, status of cognitive
function, literacy levels, sexual health, religious beliefs,
side effects of treatment, and whether signiﬁcant persons
(eg, carer, partners) accompany the patients in the pro-
cess of care. These factors inﬂuence not only the type of
treatment of choice but also the patients’ emotions, deci-
sional regret, and the degree of involvement in decision
making.32 Patients with PC aged <40 years, for example,
express signiﬁcantly high positive and negative emotions,
and partners of PC patients express more negative emo-
tions than the patient himself. The physicians’ specialty
may also unintentionally inﬂuence the physicians’ pre-
ference for treatment. Future studies should consider and
address the perspectives of the health care team on SDM
as a potential barrier for its implementation.31 In parti-
cular, interventions and components should be described
in detail so that results are interpreted appropriately, and
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interventions can be replicated and evaluated. SDM
should also be evaluated in relation to its costs and health
gains so that SDM interventions can be reliably imple-
mented. Therefore, future research needs to address the
absence of evidence on cost data.
Strengths and limitations
To our knowledge, this is the ﬁrst systematic review on SDM
compared to usual care for men faced with decisions about
PC treatment. It beneﬁts from the inclusion of international
literature without restrictions on countries or type of health
care professionals. Including RCTs allows the estimation of
causal effects with lower risk of bias. We only included
studies meeting the key features of SDM9,14,33 because of
the continuing gaps in the conceptualization and implemen-
tation of SDM. We considered studies regardless of whether
a speciﬁc decision was promoted. This was a rigorous and
focused approach although we cannot exclude the possibility
of underreported SDM characteristics in other studies. We
only included literature published in English, but we made
considerable efforts to identify all relevant studies. We
searched several sources and contacted, between 2015 and
2017, the authors of relevant abstracts with no available full-
text, thus increasing the likelihood of identifying more recent
literature. The results from our systematic review are limited
by the quantity and methodological quality of the available
literature, in particular by a dearth of outcome data, and by
lower quality reporting of outcome data. The studies focus
primarily on SDM process-related outcomes and lack impor-
tant data on health outcomes, affecting the ability to conduct
meta-analyses.
Conclusion
There is little research currently available to appropriately
evaluate the presumed beneﬁts of SDM for decisions about
PC treatment when compared to usual care. SDM may
improve knowledge and perception of being informed
and may have a positive but short-term effect on patient-
perceived QoL. The (long-term) effects of SDM are
unclear. Future rigorous research needs a consistent and
relevant set of outcomes and interventions to assess the
effects of SDM. In particular, it should address the absence
of evidence and appropriately describe and test
a reproducible form of SDM.
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Supplementary materials
Table S1 PRISMA checklist for the reporting of the systematic review
Section/topic # Checklist item Reported on
page #
TITLE
Title 1 Identify the report as a systematic review, meta-analysis, or both. 1
ABSTRACT
Structured
summary
2 Provide a structured summary including, as applicable: background; objectives; data sources; study
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results;
limitations; conclusions and implications of key ﬁndings; systematic review registration number.
1
INTRODUCTION
Rationale 3 Describe the rationale for the review in the context of what is already known. 1-2
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, inter-
ventions, comparisons, outcomes, and study design (PICOS).
2
METHODS
Protocol and
registration
5 Indicate if a review protocol exists, if and where it can be accessed (eg, Web address), and, if
available, provide registration information including registration number.
2
Eligibility criteria 6 Specify study characteristics (eg, PICOS, length of follow-up) and report characteristics (eg, years
considered, language, publication status) used as criteria for eligibility, giving rationale.
2
Information sources 7 Describe all information sources (eg, databases with dates of coverage, contact with study authors
to identify additional studies) in the search and date last searched.
2
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that
it could be repeated.
Table S2
Study selection 9 State the process for selecting studies (ie, screening, eligibility, included in systematic review, and, if
applicable, included in the meta-analysis).
2
Data collection
process
10 Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate)
and any processes for obtaining and conﬁrming data from investigators.
2
Data items 11 List and deﬁne all variables for which data were sought (eg, PICOS, funding sources) and any
assumptions and simpliﬁcations made.
2
Risk of bias in indi-
vidual studies
12 Describe methods used for assessing risk of bias of individual studies (including speciﬁcation of
whether this was done at the study or outcome level), and how this information is to be used in
any data synthesis.
2
Summary measures 13 State the principal summary measures (eg, risk ratio, difference in means). 2
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including
measures of consistency (eg, I2) for each meta-analysis.
2
Risk of bias across
studies
15 Specify any assessment of risk of bias that may affect the cumulative evidence (eg, publication bias,
selective reporting within studies).
2
Additional analyses 16 Describe methods of additional analyses (eg, sensitivity or subgroup analyses, meta-regression), if
done, indicating which were pre-speciﬁed.
2
(Continued)
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Table S1 (Continued).
Section/topic # Checklist item Reported on
page #
RESULTS
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons
for exclusions at each stage, ideally with a ﬂow diagram.
3, Figure 1
Characteristics 18 For each study, present characteristics for which data were extracted (eg, study size, PICOS,
follow-up period) and provide the citations.
3-4, Table 1
Risk of bias within
studies
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item
12).
4, Table 2
Results of individual
studies
20 For all outcomes considered (beneﬁts or harms), present, for each study: (a) simple summary data
for each intervention group (b) effect estimates and conﬁdence intervals, ideally with a forest plot.
4, 9, Figure 2,
Table 3
Synthesis of results 21 Present results of each meta-analysis done, including conﬁdence intervals and measures of
consistency.
NA
Risk of bias across
studies
22 Present results of any assessment of risk of bias across studies (see Item 15). Table 2
Additional analysis 23 Give results of additional analyses, if done (eg, sensitivity or subgroup analyses, meta-regression
[see Item 16]).
NA
DISCUSSION
Summary of
evidence
24 Summarize the main ﬁndings including the strength of evidence for each main outcome; consider
their relevance to key groups (eg, health care providers, users, and policy makers).
9, 16
Limitations 25 Discuss limitations at study and outcome level (eg, risk of bias), and at review-level (eg, incomplete
retrieval of identiﬁed research, reporting bias).
17
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications
for future research.
17
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support (eg, supply of data); role
of funders for the systematic review.
No external
funding
Notes: Reproduced from: 1For more information, visit: www.prisma-statement.org.
Table S2 Search strategy for OVID Medline
Item Searches
1 exp Decision Making/or Decision Making, Organizational/or Decision Trees/or Decision Making/or Decision Support Techniques/or
Decision Support Systems, Clinical/or Decision Making, Computer-Assisted/or exp Computer-Assisted Instruction/or exp Patient
Participation/or exp Professional-Patient Relations/or exp “Attitude of Health Personnel”/or Counseling/or exp Health Communication/
2 exp Informed Consent/
3 (choice behavior or decision making or shared decision making).mp,tw.
4 (informed adj3 (consent or choice* or decision*)).mp,tw.
5 ((decision* or decid*) adj4 (support* or aid* or tool* or instrument* or technolog* or technique* or system* or program* or algorithm*
or process* or method* or intervention* or material*)).mp,tw.
(Continued)
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Table S2 (Continued).
Item Searches
6 (decision adj3 (board* or guide* or counseling)).mp,tw.
7 (computer* adj4 decision making).mp.
8 (patient adj3 (participation or involvement or cent#d care)).mp,tw.
9 ((risk communication or risk assessment or risk information) adj4 (tool* or method*)).mp,tw.
10 interact* health communication*.mp,tw.
11 (interact* adj (internet or online or graphic* or booklet*)).mp,tw.
12 (interact* adj4 tool*).mp,tw.
13 ((interact* or evidence based) adj3 (risk information or risk communication or risk presentation or risk graphic*)).mp,tw.
14 adaptive conjoint analys#s.mp,tw.
15 or/1–14
16 (Prostat* adj3 (Neoplasm* or Cancer or tumo?r* or carcinoma)).mp,tw.
17 exp Prostatic Neoplasms/
18 16 or 17
19 15 and 18
20 (letter or letter$ or editorial or historical article or anecdote or commentary or note or case report$ or case study).pt,sh.
21 (animals not humans).sh.
22 20 or 21
23 19 not 22
24 exp Randomized Controlled Trial/or exp clinical trial/
25 randomized controlled trial.pt.
26 randomized controlled trial.sh.
27 controlled clinical trial.pt.
28 random allocation.sh.
29 double blind method.sh.
30 single blind method.sh.
31 or/24–30
32 31 not 22
33 exp clinical trial/or exp Clinical Trials as Topic/
34 clinical trial.pt.
35 ((singl$ or doubl$ or trebl$ or trpl$) adj25 (blind$ or mask$)).ti,ab.
36 (clin$ adj25 trial$).ti,ab.
37 (random$ or placebo$).ti,ab.
38 (PLACEBO or RESEARCH DESIGN).sh.
(Continued)
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Table S2 (Continued).
Item Searches
39 or/33–38
40 39 not 22
41 40 not 32
42 exp EVALUATION STUDIES/
43 (comparative study or follow up studies or prospective studies).sh.
44 (control$ or prospectiv$ or volunteer$).ti,ab.
45 or/42–44
46 45 not 22
47 46 not (32 or 41)
48 23 and (32 or 41 or 47)
Notes: *Similar strategies were developed in EMBASE (Elsevier), CINHAL (EBSCOHost), The Cochrane Library (Wiley), PsychINFO (EBSCOHost), and Scopus.
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